U.S. Markets open in 2 hrs 49 mins

The Zacks Analyst Blog Highlights: Conmed, Exactech, Covidien, Smith & Nephew and Stryker

For Immediate Release

Chicago, IL – July 24, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Conmed Corporation (CNMD), Exactech, Inc. (EXAC), Covidien Inc. (COV), Smith & Nephew plc. (SNN) and Stryker Corp. (SYK).


Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Monday’s Analyst Blog:


Conmed’s Newest Educational Program


Surgical devices and technology provider Conmed Corporation (CNMD) recently announced plans to co-develop a sequence of educational programs along with Exactech, Inc. (EXAC). Exactech provides restoration products for bone and joint replacement. The co-developed academic program is designed to improve standards of care for patients across the spectrum of knee and shoulder repair.

Conmed and Exactech plan to utilize their positional advantage and expertise to enhance patient care. The exhaustive medical educational program covers arthroscopic intervention to complete joint replacement techniques and technologies. Development of quarterly itinerary for the academic program to be launched in early 2013 is underway.

Management at Conmed believes that the educational program will provide a top-notch experience to surgeons and practitioners in related fields. The company’s alliance with Exactech will help to develop a discursive approach to surgeon education and is expected to improve the technical skill-set of the surgeons. The goal of the program is to provide excellent educational experience to orthopaedic surgeons.

The companies understand the need for advanced techniques to treat the continuum of orthopaedic injuries and appropriate training of surgeons. Furthermore, there is a lack of medical programs to address injuries ranging from soft tissue damage to joint disease. Consequently, management at Exactech asserts that there should be a paradigm shift in orthopaedic educational programs.

The educational programs will be carried out at Conmed Linvatec’s exclusive Center for Orthopaedic Education based in Largo, Florida. Conmed Linvatec is a subsidiary of Conmed Corporation. The joint development of the academic program will also provide Conmed with an opportunity to exhibit its world-class training facility in Largo to leading surgeons.

Conmed serves the arthroscopy, endosurgery and electrosurgery market and produces cardiac disposables. It also offers various training programs for clinicians. This underlines its commitment towards enhanced patient care and improved clinical results. The company serves a highly competitive market along with larger and technically more proficient companies like Covidien Inc. (COV), Smith & Nephew plc. (SNN) and Stryker Corp. (SYK).

Conmed currently retains a Zacks #2 Rank, which translates into a short-term Buy rating. We maintain our long-term Neutral recommendation on the stock.




Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339




Read the analyst report on CNMD

Read the analyst report on EXAC

Read the analyst report on COV

Read the analyst report on SNN

Read the analyst report on SYK

Zacks Investment Research

More From Zacks.com